Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
ATYR
Stock Latest News
Ratings
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
10d ago
ATYR
Premium
Ratings
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
10d ago
ATYR
Premium
The Fly
aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT
10d ago
ATYR
Premium
The Fly
aTyr Pharma management to meet with Piper Sandler
12d ago
ATYR
Premium
Ratings
Buy Rating for aTyr Pharma: Confidence in EFZO-FIT Phase 3 Trial Success
24d ago
ATYR
Premium
The Fly
aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference
26d ago
ATYR
Premium
Ratings
aTyr Pharma’s Innovative Fibrosis Treatment and Promising Pipeline Garner Buy Rating
26d ago
ATYR
Premium
The Fly
aTyr Pharma advances ATYR0101 to IND candidate stage for pulmonary fibrosis
1M ago
ATYR
Premium
Ratings
Positive Outlook for aTyr Pharma: Buy Rating Reaffirmed Amid Promising EFZO-FIT Trial Prospects
1M ago
ATYR
Premium
Ratings
Promising Outlook for aTyr Pharma: Phase 3 Study Progress and Potential Stock Upside
1M ago
ATYR
Premium
Ratings
Promising Clinical Advancements and Financial Stability Drive Buy Rating for aTyr Pharma
1M ago
ATYR
Premium
Ratings
Promising Outlook for aTyr Pharma’s Efzofitimod and Strong Financial Position Reinforce Buy Rating
1M ago
ATYR
Premium
The Fly
aTyr Pharma reports Q1 EPS (17c), consensus (19c)
1M ago
ATYR
Premium
Company Announcements
aTyr Pharma Stockholders Approve Key Proposals at Annual Meeting
1M ago
8K
ATYR
Premium
Ratings
Promising Potential of aTyr Pharma’s ATYR2810 in Glioblastoma Treatment: Analyst Recommends Buy
2M ago
ATYR
Premium
The Fly
aTyr Pharma presents preclinical data on ATYR2810 at AACR
2M ago
ATYR
Premium
Ratings
Confident Buy Rating for aTyr Pharma Amidst Promising Phase 3 Study Insights
3M ago
ATYR
Premium
The Fly
aTyr names Dalia Reyes head of commercial, global efzofitimod franchise
3M ago
ATYR
Premium
The Fly
aTyr Pharma director buys $15K in common stock
3M ago
ATYR
Premium
Market News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments
3M ago
ATYR
Premium
Ratings
Buy Rating Affirmed for aTyr Pharma Amid Strategic Trial Adjustments and Financial Stability
3M ago
ATYR
Premium
Company Announcements
aTyr Pharma’s Earnings Call Highlights Progress and Challenges
3M ago
ATYR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
